In a report released today, Boris Peaker from Cowen & Co. maintained a Hold rating on Jounce Therapeutics Inc (JNCE). The company’s shares opened today at $4.08.
According to TipRanks.com, Peaker is a 3-star analyst with an average return of 2.0% and a 40.0% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Hold analyst consensus rating for Jounce Therapeutics Inc with a $13 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.58 and a one-year low of $2.66. Currently, Jounce Therapeutics Inc has an average volume of 179.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting.
